Hidradenitis suppurativa (HS)
HUMIRA is the first and only originator biologic* indicated in the treatment of HS†
HUMIRA is indicated for the treatment of active moderate to severe HS in adult and adolescent patients (12 to 17 years of age weighing ≥30 kg), who have not responded to conventional therapy (including systemic antibiotics).
* Also known as a reference biologic.
† Comparative clinical significance has not been established.
HUMIRA’s mechanism of action*
• HUMIRA is a recombinant human
immunoglobulin (IgG1) monoclonal
antibody.1*
• HUMIRA modulates biological
responses that are induced or regulated
by TNF.1*
Did you know?
HUMIRA binds specifically to TNF-α and blocks its interaction with TNF receptors; it does not bind to lymphotoxin (TNF-β).1*
Safety information
Click here for additional information and for a link to the Product Monograph discussing:
• Contraindications in patients with severe infections such as sepsis, tuberculosis (TB) and opportunistic infections, and moderate to severe heart failure (NYHA class III/IV).
• The most serious warnings and precautions regarding hepatosplenic T-cell lymphoma, serious infections and pediatric malignancy.
• Other relevant warnings and precautions regarding concurrent administration with other biologic isease-modifying antirheumatic drugs (DMARDs) or other tumour necrosis factor (TNF) antagonists not recommended, switching between biological DMARDs, surgery, patients with congestive heart failure, hematologic events, hypersensitivity reactions, autoimmunity, immunosuppression, immunizations, infections including TB, opportunistic infections and hepatitis B virus reactivation, malignancies including malignancies in pediatric patients and young adults, lymphoma and non-lymphoma malignancy, neurologic events, uveitis and central demyelinating disorders, pregnant or nursing women, and geriatrics.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
The Product Monograph is also available by calling us at 1-866-8HUMIRA (1-866-848-6472).
* Clinical significance has not been established.
Reference:
1. HUMIRA Product Monograph. AbbVie Corporation.